Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and related neurological conditions. Its lead program, buntanetap, is being advanced for Alzheimer’s disease and Parkinson’s disease, with additional patent claims covering acute brain and nerve injuries, neuropsychiatric indications, infections of the brain, and other disease areas. The company was founded in 2008 and is headquartered in Malvern, Pennsylvania. Annovis has not commercialized any product and currently operates as a single operating segment centered on research, development, and clinical execution.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of buntanetap as a treatment for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
Research and patenting around additional uses for buntanetap in brain injury, neuropsychiatric, infectious, and oncology-related settings.
Development work on Posiphen, Posiphen Form B, and ANVS402 as related proprietary compounds.
Patent filings and composition-of-matter protection intended to extend exclusivity and support future partnering.
Customers
Annovis does not currently sell commercial products, so it has no traditional paying customer base today. Its near-term end users, if approvals are obtained, would be patients with Alzheimer’s disease, Parkinson’s disease, and potentially other neurodegenerative or neurological conditions. The company’s commercial customers would likely be healthcare providers, hospitals, specialty pharmacies, and third-party payors that determine access and reimbursement. In the current stage, the company’s key external stakeholders are clinical investigators, contract research organizations, contract manufacturers, regulators, and potential licensing or commercialization partners.
Patients with Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders who would use buntanetap or related therapies if approved.
Neurologists, memory clinics, movement-disorder specialists, and hospitals that would diagnose, prescribe, and monitor treatment.
Commercial insurers, Medicare/Medicaid, and other payors that would determine coverage, medical necessity, and reimbursement terms.
CROs, CMOs, investigators, and consultants that support development, manufacturing, and regulatory submissions.
Pharmaceutical partners that could help commercialize approved products in exchange for rights or economics.
Strategy
Annovis’ strategy is centered on advancing buntanetap through late-stage clinical development and regulatory review in Alzheimer’s disease and Parkinson’s disease. The company is also broadening the intellectual-property estate around additional neurological, infectious, and other potential indications to extend the commercial life of its platform. Because it has no product revenue and no internal sales infrastructure, financing remains a core strategic priority and the company relies on equity offerings, debt, and collaboration or licensing arrangements to fund operations. A successful strategy depends on completing trials, securing approvals, and then either building commercialization capabilities or partnering with larger pharmaceutical companies.
Clinical readouts and regulatory progress are the main value drivers for a company with no commercial revenue.
The company states it does not have sufficient capital to fund operations for the next 12 months and needs additional funding to continue development.
Patent protection is essential for future exclusivity, partnering leverage, and eventual commercial value.
The company has no internal sales, marketing, or distribution capabilities and will need a route to market if approval is achieved.
Geography
Annovis is headquartered in Malvern, Pennsylvania, and substantially all of its assets are located in the United States. The company’s development and financing activities are primarily U.S.-based, and it currently has no commercial revenue footprint. Its patent strategy explicitly includes protection in the United States and jurisdictions outside the United States, indicating an intent to preserve optionality for future international development or partnering. If products are approved, geography will matter materially because reimbursement, regulatory requirements, and commercialization capabilities differ by country.
Risks
Annovis faces the classic risks of a clinical-stage biotechnology company: trial failure, regulatory delay, and the possibility that approved products never achieve commercial uptake. The company has no product revenue, limited cash runway, and a stated need for additional capital, so financing risk is immediate and material. It also depends on CROs and CMOs for trial execution and manufacturing, which creates quality, compliance, and supply-chain risk outside its direct control. If buntanetap is approved, reimbursement, pricing pressure, and competition from much larger pharmaceutical companies could materially limit adoption and economics.
- Need for additional capitalImpact: CriticalLikelihood: High
The company states it does not have sufficient capital to fund operations for the next 12 months and will need substantial additional financing.
Exposure: Operating runway and ability to continue clinical development
- Clinical development failureImpact: CriticalLikelihood: Medium
Buntanetap is still in development, and negative trial results would materially impair the company’s prospects.
Exposure: Lead asset value and future approval path
- Commercialization and reimbursement riskImpact: HighLikelihood: Medium
Even if approved, third-party payors may not view the therapy as medically necessary or cost-effective.
Exposure - Manufacturing and CMO dependenceImpact: HighLikelihood: Medium
The company relies on third-party manufacturers and has limited control over cGMP compliance and supply continuity.
Exposure: Trial supply and future commercial supply
- Competition from larger biopharma companiesImpact: MediumLikelihood: Medium
Competitors have greater resources, broader pipelines, and more established commercialization capabilities.
Exposure: Market share and partnering leverage
Accounting
Judgemental itemsTrial-related services are often billed after services are performed, requiring estimates for expenses and liabilities at period-end.
Impact: Can materially affect quarterly R&D expense and accrued liabilities
The company recorded gains and losses from changes in the fair value of warrants, which can be volatile and non-cash.
Impact: Can distort net income/loss trends and comparability
As a development-stage company, equity awards are an important part of employee compensation and affect reported operating costs.
Impact: Raises G&A and R&D expenses without cash outflow
Management states current cash is insufficient to fund operations for at least twelve months, making liquidity disclosure central to analysis.
Impact: Affects investor assessment of financing risk and dilution
Similar listed companies
Publicly listed companies with a comparable business focus.
Anavex Life Sciences Corp
AVXL · Biological Products, (No Diagnostic Substances)
Passage BIO, Inc.
PASG · Biological Products, (No Diagnostic Substances)
BioVie Inc
BIVIW · Pharmaceutical Preparations
ProMIS Neurosciences Inc.
PMN · Pharmaceutical Preparations
Kalaris Therapeutics, Inc.
KLRS · Biological Products, (No Diagnostic Substances)
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
Last updated: 24/09/2026